April 26, 2005
AidsStocks.com: HIV / Aids Industry Report Features Abbott Pharmaceuticals, Aethlon Medical, Sanofi Pasteur and CytRX Corporation
POINT ROBERTS, Wash.; April 26,2005, www.AidsStocks.com, an investor and industry news portal for the Aids sector within the www.InvestorIdeas.com content portfolio is pleased to announce that the industry analyst report, Major Developments in the Treatment of HIV/Aids, by Griffin Securities is now available for review on the AidsStocks.com industry portal. Companies featured in the report include Abbott Pharmaceuticals (ABT Aethlon Medical (OTCBB: AEMD Sanofi Pasteur (SNY) and CytRX Corporation (CYTR).
The report features various approaches to attacking HIV currently in development including www.AidsStocks.coms featured company, Aethlon Medical”s (OTCBB: AEMD) Hemopurifier(tm) which, according to the report, “may offer exciting adjunct solutions to traditional anti-viral therapy”.
Griffin, HIV/AIDS Industry Report, April 2005
Analysts: Chrystyna Bedrij, Thomas Finnigan, Scott C. Matchett, CFA
Link to Full Report: http://www.aidsstocks.com/Aids_Stocks/News/HIVINDUSTRYREPORT15BB0D.pdf
The AidsStocks.com website does not make recommendations, but offers a unique free information portal regarding AIDS Research, Biotech Companies in AIDS Research news, HIV diagnostics, therapeutics, treatments, Infectious Disease Research, news, articles and participating public companies.
Additional Biotech Stocks Info: http://www.investorideas.com/Research/Industries/Biotech.asp
Featured Company: Aethlon Medical (OTCBB: AEMD)
Aethlon Medical, Inc. (OTCBB: AEMD) is pioneering the development of medical devices that are able to treat drug-resistant HIV. Aethlon”s patented Hemopurifier? technology is a combination product that converges the established principals of hemodialysis and affinity chromatography to replicate the immune response of clearing viruses and toxins from circulation prior to cell and organ infection. The Hemopurifier? is also positioned as conjunctive therapy to enhance and prolong current drug regimens through the direct clearance of mutant HIV strains. Human studies are scheduled to begin in India in the coming months, and U.S. Human trials are expected to begin by year-end. Aethlon has an experienced management team, which receives support and guidance from globally recognized science advisors representing the both the infectious disease and dialysis industries.
Aethlon Medical (OTCBB: AEMD) was a featured presenting company in the online www.HomelandDefensestocks.com. Audio Conference April 6th, 2005. The conference can still be accessed online at the following address: http://www.homelanddefensestocks.com/forums/Portals/homelanddefense2.aspx
About Griffin: Griffin Group plc is listed on the London Stock Exchange, Alternative Investment Market, under the symbol: “GFF” and as an ADR sponsored by The Bank of New York under the symbol “GGPFY”.
Griffin”s New York offices: Griffin Securities, Inc
17 State Street, NY, NY 10004
Disclaimer: ECON Investor Relations Inc is the owner of the domain www.AidsStocks.com. Our site does not make recommendations, but offers a unique information portal to investors to research news, articles, and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell any specific products or securities. All investments involve risk. Although we attempt to research thoroughly, we offer no guarantees as to the accuracy of any information presented. We encourage all investors to use our sites only as a resource to further their own research. The site is currently compensated for by its featured companies, Aethlon Medical: Three thousand dollars per month, plus restricted shares equivalent to five thousand dollars per month.
Contact:
Dawn Van Zant / Trevor Ruehs
Toll free: 800-665-0411
Email: dvanzant@investorideas.com or truehs@investorideas.com
